3Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turn over may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Circulation,2000,102:2700. 被引量：1
4Satoh M, Nakamura M, Saitoh H, et al. Aldosterone synthese(CYP11 B2 ) expression and myocardial fibrosis in the failing human heart. Clin Sci (Lond) ,2002,62:723-731. 被引量：1
5Rauersachs J, Heck M, Fraccarollo D, et al. Addition of spironolactone to angiotensin-convention enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide syntha 被引量：1
6Rocha R, Williams GH. Rationale for the use of Aldosterone antagonists in congestive heart failure. Drugs, 2002,62:723-731. 被引量：1
7Bristow MR. What type of beta-blocker should be used to treat chronic heart failure? Circulation, 2000, 10:484-486. 被引量：1
8De Mey C. Inverse PK/PD: estimation and differentiation of bioavailability from effect kinetics-observations with beta-adrenoceptor antagonists. Int J Clin Pharmacol Ther, 1997, 35: 453-457. 被引量：1
9Vanhees L, Aubert A, Fagard R, et al. Influence of beta 1- versus beta 2-adrenoceptor blockade on left ventricular function in humans. J Cardiovasc Pharmacol, 1986, 8: 1086-1091. 被引量：1
10De Mey C, Breithaupt-Grogler K, Schloos J, et al. Reproducibility and consistency of the responses to supine bicycle ergometry; evaluation in conjunction with beta 1-adrenoceptor occupancies. Br J Clin Pharmacol, 1994, 38: 480-483. 被引量：1
